ONCAlert | 2018 ASCO Annual Meeting

Dr. Matthew H. Kulke Talks About Telotristat Etiprate Benefitting Carcinoid Syndrome Patients

Published Online: 8:24 PM, Mon October 19, 2015

 

Matthew H. Kulke, MD, director of the Program in Neuroendocrine and Carcinoid Tumors at Dana-Farber Cancer Institute in Boston, talks about the strong potential of telotristat etiprate, a novel serotonin synthesis inhibitor.

 

 

Kulke says telotristat etiprate could potentially represent a new class of treatment for patients with carcinoid syndrome, due to its ability to decrease serotonin levels. He adds that serotonin levels could present a problem for patients with carcinoid syndrome and lower levels may help avoid heart disease and fibrosis of the intestines.



Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.